Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Lilly Oncology VP Out

January 25, 2011 6:20 am | News | Comments

Eli Lilly and Company announced that John H. Johnson, senior vice president and president of Lilly Oncology, has resigned effective January 28, 2011. A successor will be announced in the coming weeks.


J & J Bottom Line Hit By Recalls

January 25, 2011 6:18 am | News | Comments

Health care giant Johnson & Johnson, hammered by numerous recalls that have kept some popular nonprescription medicines and other products off the market, posted a 12 percent profit decline and a 5.5 percent drop in revenue for the fourth quarter.


Liquid Handling Robot

January 24, 2011 7:35 am | Product Releases | Comments

Hamilton Robotics has integrated Peak Robotics' KiNEDx robot series with Hamilton's MICROLAB STAR automated liquid handling workstation. The KiNEDx 4- and 5-axis robots increase the STAR's access to microplate samples and third-party devices.


Clone Screening

January 24, 2011 7:12 am | Product Releases | Comments

Genetix announced the launch of its ClonePix 2 system – the second generation system based on the company’s well-established and successful technology and chemistries for clone screening and selection.


Gene Sequencing Not Sufficient in Disease Modeling

January 24, 2011 7:08 am | News | Comments

Despite what you might have heard, genetic sequencing alone is not enough to understand human disease. Researchers have shown that functional tests are absolutely necessary to understand the biological relevance of the results of sequencing studies.


HIV Finding May Lead to New Drugs

January 24, 2011 6:58 am | News | Comments

HIV adapts in a surprising way to survive and thrive in its hiding spot within the human immune system, scientists have learned. While the finding helps explain why HIV remains, it also offers researchers a new, unexpected way to try to stop the virus.


PerkinElmer Adds Sequencing Service

January 24, 2011 6:55 am | News | Comments

PerkinElmer, Inc. announced the launch of a next generation DNA sequencing and data analysis services for genome sequencing at the company's lab in Branford, Conn.


Teva Signs $1.5B Credit Facility

January 24, 2011 6:49 am | News | Comments

Drug developer Teva Pharmaceutical Industries Ltd. said it signed a new three-year, $1.5 billion credit facility. The company said the new facility is part of its strategy to secure liquidity for future business needs through revolving credit lines.


Pharmasset, Shareholders Offering 3.3M Shares

January 24, 2011 6:47 am | News | Comments

Pharmasset Inc. said it is publicly offering just under $106.6 million in common stock, with an additional $46.3 million being offered by shareholders.


Bayer's Gadobutrol Receives Panel Nod

January 24, 2011 6:43 am | News | Comments

Bayer HealthCare Pharmaceuticals Inc. said that a Food and Drug Administration advisory panel has recommended approval of its injectable imaging agent for use in MRI scans.


FDA Approves New Depression Drug

January 24, 2011 6:38 am | News | Comments

Biotechnology company Clinical Data Inc. said the Food and Drug Administration approved the major depressive disorder treatment Viibryd. The company said the drug should be available in U.S. pharmacies in the second quarter.


Teva Buys Partial Ownership in Rexahn

January 24, 2011 6:30 am | News | Comments

Rexahn Pharmaceuticals Inc. said that Teva Pharmaceutical Industries Ltd. bought $3.95 million of the company's stock in a private offering. The investment gives Teva a 6.29 percent ownership stake in Rexahn.


HGS Adds Ex-Wyeth CFO to Board

January 24, 2011 6:22 am | News | Comments

Lupus drug developer Human Genome Sciences Inc. said it appointed former Wyeth Chief Financial Officer Greg Norden to its board of directors.


FDA Questions Vivus on Birth Defects

January 24, 2011 6:16 am | News | Comments

The Food and Drug Administration has asked Vivus Inc. to study the rate of side effects associated with one of the ingredients of its obesity drug candidate, Qnexa.


CHMP Recommends Trobalt for Seizures

January 24, 2011 6:11 am | News | Comments

A regulatory committee recommended that a seizure drug developed by GlaxoSmithKline and Valeant Pharmaceuticals be approved in the European Union, the companies said.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.